Arrowhead CEO Chris Anzalone maps the future of RNAi therapeutics
Start here
On The BioCentury Show, Arrowhead Pharmaceuticals CEO Chris Anzalone laid out his view of where RNAi therapy is headed. He argues that siRNAs outperform antisense oligonucleotides for pure gene silencing on three fronts: durability of effect, depth of knockdown and safety, while ASOs keep a role for exon skipping and reaching a broader range of tissues. In his framing, the decisive challenge for scaling the platform is delivery beyond the liver, extending siRNA action into the central nervous system, adipose tissue, lung, muscle and eye. Achieving reliable extrahepatic delivery is, in his account, the gate through which RNAi must pass to become a broadly applicable therapeutic class.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- biocentury.comPickThe future of RNAi with Arrowhead’s Chris Anzalone on The BioCentury Show
Arrowhead Pharmaceuticals CEO Chris Anzalone lays out his view of RNAi's future on The BioCentury Show, arguing siRNA beats ASOs for pure gene silencing on durability, knockdown depth and safety, while ASOs retain value for exon skipping and broader tissue access. He frames delivery beyond the liver, into CNS, adipose, lung, muscle and eye, as the key to scaling the platform.
Heat trend for this story
Heat now 6·Peak in the comparable set 7 (Oct 17 16:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.